Qurient Co. Ltd., a spin-off of Institut Pasteur Korea (IPK), was listed on KOSDAQ on Feb. 29, 2016. Qurient is the first biotech company listed on KOSDAQ through the open innovation and project management system. Since IPK established Qurient in 2008, Qurient has run three preclinical programs and ushered a drug candidate to the global clinical development stage, including drug-resistant tuberculosis candidate Q203 licensed from IPK.


Source: Gyeonggi Ilbo (2 March, 2016)